Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

Nonalcoholic fatty liver disease (NAFLD) is considered the next major health epidemic with an estimated 25% worldwide prevalence. No drugs have yet been approved and NAFLD remains a major unmet need. Here, we identify MCJ (Methylation-Controlled J protein) as a target for non-alcoholic steatohepatit...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbier-Torres, Lucía, Fortner, Karen A., Iruzubieta, Paula, Delgado, Teresa C., Giddings, Emily, Chen, Youdinghuan, Champagne, Devin, Fernández-Ramos, David, Mestre, Daniela, Gomez-Santos, Beatriz, Varela-Rey, Marta, de Juan, Virginia Gutiérrez, Fernández-Tussy, Pablo, Zubiete-Franco, Imanol, García-Monzón, Carmelo, González-Rodríguez, Águeda, Oza, Dhaval, Valença-Pereira, Felipe, Fang, Qian, Crespo, Javier, Aspichueta, Patricia, Tremblay, Frederic, Christensen, Brock C., Anguita, Juan, Martínez-Chantar, María Luz, Rincón, Mercedes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334216/
https://www.ncbi.nlm.nih.gov/pubmed/32620763
http://dx.doi.org/10.1038/s41467-020-16991-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334216/
https://www.ncbi.nlm.nih.gov/pubmed/32620763
http://dx.doi.org/10.1038/s41467-020-16991-2

Ejemplares similares